ArticleACS pharmacology & translational science2023
Preventive and Therapeutic Effects of
Article in ACS pharmacology & translational science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 9 citations in OpenAlex.
- Effect of Silibinin on Human Pancreatic Lipase Inhibition and Gut Microbiota in Healthy Volunteers: A Randomized Controlled Trial.International journal of molecular sciences · 2024Trial
- From Ethnobotany to Pharmacology: A Comprehensive Review of Selected Asteraceae Species Highlighting Phytochemical Composition, Traditional Uses, and Diverse Pharmacological Activities.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Comparative Evaluation of Gold Nanoparticles, Extracts, and Topical Formulations Prepared withACS pharmacology & translational science · 2026Article
- Antidiabetic Potential ofPlants (Basel, Switzerland) · 2025Review
- Biosynthesized Gold Nanoparticles fromAntibiotics (Basel, Switzerland) · 2025Article
- Article
- Article
- Looking beyond silybin: the importance of other silymarin flavonolignans.Frontiers in pharmacology · 2025Article
- Synthesis, pharmacological evaluation, andHeliyon · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS) has become an increasing global health problem, which leads to cardiovascular diseases and type 2 diabetes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.